Meropenem

Meropenem, the active ingredient in Meropenem, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, septicemia and meningitis in hospitalized patients.

GNH USA supplies Meropenem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infection: provides rapid bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infection: eliminates resistant Gram‑negative and Gram‑positive pathogens in the urinary tract. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant organisms. - Septicemia: offers systemic coverage for bloodstream infections with high mortality risk. - Meningitis: penetrates the cerebrospinal fluid to combat bacterial meningitis effectively.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild transaminase increase. - Injection site reaction: pain or erythema at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Anaphylaxis: acute hypersensitivity requiring emergency care. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function in susceptible individuals. - Hypersensitivity syndrome: systemic rash, fever and organ involvement.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dose in patients with impaired clearance. - Allergy: avoid in individuals with known carbapenem hypersensitivity. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: monitor for increased seizure activity. - Hepatic monitoring: observe liver enzymes during prolonged treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug‑drug interactions should be reviewed prior to initiation.

Major Interactions (Avoid): - Valproic acid: may lower seizure threshold and increase neurotoxicity. - Ganciclovir: reduced antiviral efficacy due to decreased plasma levels. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics: heightened risk of electrolyte imbalance and renal dysfunction. - Aminoglycosides: additive nephrotoxic potential; monitor renal parameters. - Warfarin: possible alteration of INR; check coagulation status regularly.